We have carefully read the recent article by Fan et al. that *Amhr2*^*cre*/+^-mediated deletion produces "global" knockouts rather than tissue specific conditional knockouts ([@B1]). Such a major observation has not been explicitly recorded in the \>100 publications that demonstrate tissue-specific conditional deletions using this *Amhr2*^*tm*3(*cre*)*Bhr*^ mouse \[MGI ID: 3042214; noted previously in ([@B2])\]. Furthermore, the authors directed their findings toward questioning published reports which disprove a role for the mitochondrial translocator protein (TSPO) in cholesterol transport and steroidogenesis, one of which was based on *Amhr2*^*cre*/+^-mediated conditional *Tspo* knockout mice ([@B3]).

Transmission From the Male or Female Parent Matters in *Amhr2-Cre* Activity {#s1}
===========================================================================

For cell type specific deletions using *Amhr2*^*cre*/+^ expressing mice ([@B4]), it is important to use male *Amhr2*^*cre*/+^ mice in the breeding scheme. This is information that has been shared among colleagues who have previously used *Amhr2*^*cre*/+^ mice in their studies. Accordingly, we have used males to transmit *Amhr2*^*cre*/+^ with confirmed conditional recombination for floxed targets ([@B3], [@B5]--[@B9]). Separate from our TSPO studies, there have indeed been incidents with breeding of female *Amhr2*^*cre*/+^ mice that resulted in global deletions. For example: when both male and female *Amhr2*^*cre*/+^ mice were used to delete *Smo*, global knockouts of which are embryonic lethal ([@B10]), *Amhr2*^*cre*/+^ conditional knockouts were obtained only when the sire harbored *cre* (unpublished). The breeding scheme was subsequently restricted to using male *Amhr2*^*cre*/+^ mice ([@B8]). This is consistent with male-restricted breeding schemes indicated by many different groups ([@B11]--[@B21]). So, we agree with findings reported by Fan et al. regarding global deletions ([@B1]), but caution that this is the case only when female *Amhr2*^*cre*/+^ mice are used \[gender of *Amhr2*^*cre*/+^ mice used in his publication was not indicated ([@B1])\]. This report therefore does not necessitate reinterpretation of any previous data on *Amhr2*^*cre*/+^ conditional knockouts unless female *Amhr2*^*cre*/+^ mice were inadvertently used.

For some transgenic lines, it is known that *cre* activity can vary based on whether the transgene is inherited from the male or female parent. As a knock-in *Amhr2*^*cre*/+^ allele, expression is anticipated to reflect endogenous *Amhr2* expression; therefore, this aberration is indeed unexpected. As *Amhr2* knockout mice are viable ([@B22]), there appears to be little impact if there is indeed endogenous *Amhr2* expression in the inner cell mass and trophoblast layer. It would also be valuable to test if this phenotype can be reproduced with the newly available *Amhr2*^*em*1(*cre*)*Smoc*^ knock-in mice (NM-KI-190012; Shanghai Model Organisms).

TSPO Is Not Involved in *de novo* Steroidogenesis {#s2}
=================================================

Irrespective of method used or the timing of recombination, the conclusion for TSPO-loss of function with regard to *de novo* steroidogenesis is quite consistent \[reviewed in ([@B23])\]. It does not affect viability (whole animal) nor does it affect mitochondrial cholesterol import in phenotypes reported by several independent laboratories (including ours) that have generated global *Tspo* knockouts using *Ddx4*-cre ([@B24]), *Pgk1*-cre ([@B25]), *Prm*-cre ([@B26]), *Camk2a*-cre ([@B27]), and *Best1*-cre ([@B28]). The important points are: (a) Four of the above global knockouts generated were using independently produced *Tspo* floxed mice ([@B24]--[@B27]). (b) One of the global knockouts ([@B28]), was generated using the same *Tspo* floxed mouse used by the Papadopoulos group that includes this study by Fan et al. ([@B1]). (c) All the global knockouts were derived by recombination of *Tspo*-floxed alleles in the germline \[expected ([@B24], [@B26]) or aberrant ([@B27], [@B28])\] or in early diploid cells ([@B25]). Therefore, these studies do describe *Tspo* knockouts that lack expression in the inner cell mass, as described for the *Amhr2*^*cre*/+^ -mediated *Tspo* deletion by Fan et al. ([@B1]), and reveal no effects on embryonic development. (d) The proposed mechanism of TSPO function in steroidogenesis is by mediating mitochondrial cholesterol import, without which *de novo* steroidogenesis cannot occur \[reviewed in ([@B29])\]. However, "subtle steroidogenic abnormalities" indicated in post-pregnenolone intermediates observed with TSPO loss in one study ([@B27]), is not associated with mitochondrial cholesterol import, but indicative of systemic perturbations across all TSPO expressing tissues involved in energy metabolism ([@B30]), and could certainly include effects mediated by the pituitary ([@B31]). It must be noted that high TSPO expression is not restricted to steroidogenic cells ([@B32]), and the question has always been whether it impacts *de novo* steroidogenesis supporting its conjectural function first proposed in the late 1980s \[reviewed in ([@B33])\].

Compared to TSPO studies that refute a role in *de novo* steroidogenesis ([@B3], [@B24]--[@B26], [@B32], [@B34], [@B35]), there is no straightforward path to explaining the recent contradictory reports made by the Papadopoulos group using mice ([@B1], [@B36]), rats ([@B37]), and cells ([@B38]) that support their long-promulgated view of TSPO function in mitochondrial cholesterol import. We have previously pointed out these concerns ([@B2], [@B39]), and new evidence from independent groups continue to disassociate anticipated TSPO effects in astrocytes ([@B40]), microglia ([@B35]), and retinal pigment epithelial cells ([@B41]). In reference to this recent manuscript by Fan et al. ([@B1]), they report a \~50% decrease in circulating testosterone while in their previous study using mice from the same background and with confirmed Leydig cell *Tspo* deletions, they reported no effect on circulating testosterone levels ([@B36]). Despite lower testosterone, there was no evidence of hypogonadism; in fact, testis size significantly increased in their *Amhr2*^*cre*/+^ *Tspo* knockout mice ([@B1]). Furthermore, this study by Fan et al. used RNA-seq datasets that we generated for the *Ddx4*-cre *Tspo*-knockout adrenal ([@B24]) and *Prm*-cre *Tspo*-knockout lung ([@B26]), to suggest that there is some sort of steroidogenic compensation to *Tspo* deletion, when we found no such links in our respective original studies. These RNA-seq datasets show that a compensation to mitochondrial cholesterol import does not exist as the major players implicated in this process were unchanged. Nonetheless, Fan et al. seem to shift context toward explaining TSPO-associated effects on mitochondrial membrane potential and metabolism ([@B1]), distinct from the asserted cholesterol binding-transport function ([@B33]). Although logical, these elucidations are unrelated and do not justify that TSPO loss-of-function is linked to the first step in steroid biosynthesis as opined throughout the text. There is no loss to mitochondrial membrane potential in hepatocytes ([@B42]), or Leydig cells ([@B32]), associated with TSPO deletion as suggested ([@B1]). Regardless, TSPO is clearly poised to affect cellular function and physiology. Based on *Tspo* knockout studies, this is via a primary function without impact on *de novo* steroid biosynthesis.

Concluding Remarks {#s3}
==================

This manuscript obviously represents a commendable effort by Papadopoulos and colleagues to seek evidence linking TSPO and mitochondrial cholesterol import for steroidogenesis. Nonetheless, previous demonstrations that TSPO is not involved in *de novo* steroidogenesis remain substantive and justified. Moving forward, we believe it is important to first acknowledge that high TSPO expression is not only seen in steroidogenic cells; a unifying investigation into mechanism of action across different cell types will be necessary to seek a functional designation for this protein.
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